Geovax Labs Inc
Company Profile
Business description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Contact
1955 Lake Park Drive
Suite 300
SmyrnaGA30080
USAT: +1 678 384-7220
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
Weak investor sentiment for cheap ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.60 | 41.90 | 0.47% |
| CAC 40 | 8,062.31 | 86.19 | 1.08% |
| DAX 40 | 24,401.70 | 410.43 | 1.71% |
| Dow JONES (US) | 49,298.25 | 356.35 | 0.73% |
| FTSE 100 | 10,219.11 | 144.82 | -1.40% |
| HKSE | 26,080.31 | 181.70 | 0.70% |
| NASDAQ | 25,326.13 | 258.33 | 1.03% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,179.90 | 144.20 | 1.11% |
| S&P 500 | 7,259.22 | 58.47 | 0.81% |
| S&P/ASX 200 | 8,778.80 | 43.80 | 0.50% |
| SSE Composite Index | 4,159.60 | 47.45 | 1.15% |